Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.560
-0.040 (-2.50%)
Jul 24, 2025, 2:53 PM - Market open
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
152.68M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MIST News
- 6 days ago - Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution - Seeking Alpha
- 13 days ago - Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge - Benzinga
- 13 days ago - Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants - GlobeNewsWire
- 13 days ago - Milestone Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 13 days ago - Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray - GlobeNewsWire
- 17 days ago - Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst - Seeking Alpha
- 5 weeks ago - Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire